Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake

European Journal of Pharmacology

Volumn 609, Issue 1-3, 2009, Pages 88-95

  Yue, Jiang ^b   Khokhar, Jibran ^a   Miksys, Sharon ^a   Tyndale, Rachel F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b WUHAN UNIVERSITY   (China)

Author keywords

Alcohol; Cytochrome P450 2B1 2; Cytochrome P450 2E1; Ethanol self administration; Nicotine

Indexed keywords

ALCOHOL; CYTOCHROME P450 2B1; CYTOCHROME P450 2B2; CYTOCHROME P450 2D1; CYTOCHROME P450 2E1; NICOTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; LIVER LEVEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN METABOLISM; RAT;

ALCOHOL DRINKING; ANIMALS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CYTOCHROME P-450 CYP2B1; CYTOCHROME P-450 CYP2E1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INDUCTION; ETHANOL; HYDROGEN-ION CONCENTRATION; LIVER; MALE; MICROSOMES, LIVER; NICOTINE; RATS; RATS, WISTAR; TIME FACTORS;

EID: 64549154408     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.03.015     Document Type: Article

References (69)

1. Adir J., Wildfeuer W., and Miller R.P. Effect of ethanol pretreatment on the pharmacokinetics of nicotine in rats. J. Pharmacol. Exp. Ther. 212 (1980) 274-279
2. Batel P., Pessione F., Maitre C., and Rueff B. Relationship between alcohol and tobacco dependencies among alcoholics who smoke. Addiction 90 (1995) 977-980
3. Benowitz N.L., and Jacob III P. Daily intake of nicotine during cigarette smoking. Clin. Pharmacol. Ther. 35 (1984) 499-504
4. Bierut L.J., Rice J.P., Goate A., Hinrichs A.L., Saccone N.L., Foroud T., Edenberg H.J., Cloninger C.R., Begleiter H., Conneally P.M., Crowe R.R., Hesselbrock V., Li T.K., Nurnberger Jr. J.I., Porjesz B., Schuckit M.A., and Reich T. A genomic scan for habitual smoking in families of alcoholics: common and specific genetic factors in substance dependence. Am. J. Med. Genet., A 124 (2004) 19-27
5. Blomqvist O., Ericson M., Johnson D.H., Engel J.A., and Soderpalm B. Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment. Eur. J. Pharmacol. 314 (1996) 257-267
6. Buczek Y., Tomkins D.M., Le A.D., and Sellers E.M. Opposite effects of Ro 15-4513 on acquisition and maintenance of ethanol drinking behavior in male Wistar rats. Alcohol Clin. Exp. Res. 21 (1997) 1667-1675
7. Caro A.A., and Cederbaum A.I. Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 27-42
8. Chang T.K., Weber G.F., Crespi C.L., and Waxman D.J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53 (1993) 5629-5637
9. Clark A., Lindgren S., Brooks S.P., Watson W.P., and Little H.J. Chronic infusion of nicotine can increase operant self-administration of alcohol. Neuropharmacology 41 (2001) 108-117
10. Clarke P.B., and Kumar R. The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br. J. Pharmacol. 78 (1983) 329-337
11. Corrigall W.A., Coen K.M., and Adamson K.L. Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res. 653 (1994) 278-284
12. DiFranza J.R., and Guerrera M.P. Alcoholism and smoking. J. Stud. Alcohol 51 (1990) 130-135
13. Edwards R.J., Price R.J., Watts P.S., Renwick A.B., Tredger J.M., Boobis A.R., and Lake B.G. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab. Dispos. 31 (2003) 282-288
14. Eliasson E., Johansson I., and Ingelman-Sundberg M. Ligand-dependent maintenance of ethanol-inducible cytochrome P-450 in primary rat hepatocyte cell cultures. Biochem. Biophys. Res. Commun. 150 (1988) 436-443
15. Goldman D., Oroszi G., and Ducci F. The genetics of addictions: uncovering the genes. Nat. Rev., Genet. 6 (2005) 521-532
16. Gonzalez F.J. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat. Res. 569 (2005) 101-110
17. Gonzales R.A., Job M.O., and Doyon W.M. The role of mesolimbic dopamine in the development and maintenance of ethanol reinforcement. Pharmacol. Ther. 103 (2004) 121-146
18. Hesse L.M., Venkatakrishnan K., Court M.H., von Moltke L.L., Duan S.X., Shader R.I., and Greenblatt D.J. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab. Dispos. 28 (2000) 1176-1183
19. Hesse L.M., He P., Krishnaswamy S., Hao Q., Hogan K., von Moltke L.L., Greenblatt D.J., and Court M.H. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14 (2004) 225-238
20. Hoet P., Buchet J.P., Sempoux C., Haufroid V., Rahier J., and Lison D. Potentiation of 2,2-dichloro-1,1,1-trifluoroethane (HCFC-123)-induced liver toxicity by ethanol in guinea-pigs. Arch. Toxicol. 76 (2002) 707-714
21. Howard L.A., Micu A.L., Sellers E.M., and Tyndale R.F. Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver. J. Pharmacol. Exp. Ther. 299 (2001) 542-550
22. Joshi M., and Tyndale R.F. Induction and recovery time course of rat brain CYP2E1 after nicotine treatment. Drug Metab. Dispos. 34 (2006) 647-652
23. Kessova I.G., Leo M.A., and Lieber C.S. Effect of beta-carotene on hepatic cytochrome P-450 in ethanol-fed rats. Alcohol Clin. Exp. Res. 25 (2001) 1368-1372
24. Kocarek T.A., Schuetz E.G., and Guzelian P.S. Differentiated induction of cytochrome P450b/e and P450p mRNAs by dose of phenobarbital in primary cultures of adult rat hepatocytes. Mol. Pharmacol. 38 (1990) 440-444
25. Le A.D., Corrigall W.A., Harding J.W., Juzytsch W., and Li T.K. Involvement of nicotinic receptors in alcohol self-administration. Alcohol Clin. Exp. Res. 24 (2000) 155-163
26. Le Houezec J., Jacob III P., and Benowitz N.L. A clinical pharmacological study of subcutaneous nicotine. Eur J Clin Pharmacol. 44 (1993) 225-230
27. Leclercq I.A., Farrell G.C., Field J., Bell D.R., Gonzalez F.J., and Robertson G.R. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest. 105 (2000) 1067-1075
28. Lee A.M., Miksys S., Palmour R., and Tyndale R.F. CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment. Neuropharmacology 50 (2006) 441-450
29. Lieber C.S. Mechanisms of ethanol-drug-nutrition interactions. J. Toxicol., Clin. Toxicol. 32 (1994) 631-681
30. Lieber C.S. Cytochrome P-4502E1: its physiological and pathological role. Physiol. Rev. 77 (1997) 517-544
31. Lieber C.S. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)-a review. Alcohol Clin. Exp. Res. 23 (1999) 991-1007
32. Mann A., Miksys S., Lee A., Mash D.C., and Tyndale R.F. Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology 55 (2008) 1147-1155
33. Matsumoto H., Matsubayashi K., and Fukui Y. Evidence that cytochrome P-4502E1 contributes to ethanol elimination at low doses: effects of diallyl sulfide and 4-methyl pyrazole on ethanol elimination in the perfused rat liver. Alcohol Clin. Exp. Res. 20 (1996) 12A-16A
34. Matta S.G., Balfour D.J., Benowitz N.L., Boyd R.T., Buccafusco J.J., Caggiula A.R., Craig C.R., Collins A.C., Damaj M.I., Donny E.C., Gardiner P.S., Grady S.R., Heberlein U., Leonard S.S., Levin E.D., Lukas R.J., Markou A., Marks M.J., McCallum S.E., Parameswaran N., Perkins K.A., Picciotto M.R., Quik M., Rose J.E., Rothenfluh A., Schafer W.R., Stolerman I.P., Tyndale R.F., Wehner J.M., and Zirger J.M. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl). 190 (2007) 269-319
35. Micu A.L., Miksys S., Sellers E.M., Koop D.R., and Tyndale R.F. Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism. J. Pharmacol. Exp. Ther. 306 (2003) 941-947
36. Miksys S., Hoffmann E., and Tyndale R.F. Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem. Pharmacol. 59 (2000) 1501-1511
37. Miksys S., Rao Y., Sellers E.M., Kwan M., Mendis D., and Tyndale R.F. Regional and cellular distribution of CYP2D subfamily members in rat brain. Xenobiotica 30 (2000) 547-564
38. Nakayama H., Okuda H., Nakashima T., Imaoka S., and Funae Y. Nicotine metabolism by rat hepatic cytochrome P450s. Biochem. Pharmacol. 45 (1993) 2554-2556
39. Patten C.J., Thomas P.E., Guy R.L., Lee M., Gonzalez F.J., Guengerich F.P., and Yang C.S. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem. Res. Toxicol. 6 (1993) 511-518
40. Peter R., Bocker R., Beaune P.H., Iwasaki M., Guengerich F.P., and Yang C.S. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 3 (1990) 566-573
41. Rae J.M., Johnson M.D., Lippman M.E., and Flockhart D.A. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther. 299 (2001) 849-857
42. Roberts B.J., Song B.J., Soh Y., Park S.S., and Shoaf S.E. Ethanol induces CYP2E1 by protein stabilization. Role of ubiquitin conjugation in the rapid degradation of CYP2E1. J. Biol. Chem. 270 (1995) 29632-29635
43. Rotger M., Colombo S., Furrer H., Bleiber G., Buclin T., Lee B.L., Keiser O., Biollaz J., Decosterd L., and Telenti A. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 15 (2005) 1-5
44. Ryan D.E., Koop D.R., Thomas P.E., Coon M.J., and Levin W. Evidence that isoniazid and ethanol induce the same microsomal cytochrome P-450 in rat liver, an isozyme homologous to rabbit liver cytochrome P-450 isozyme 3a. Arch. Biochem. Biophys. 246 (1986) 633-644
45. Schoedel K.A., and Tyndale R.F. Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications. Biochim. Biophys. Acta. 1619 (2003) 283-290
46. Schoedel K.A., Sellers E.M., and Tyndale R.F. Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochem. Pharmacol. 62 (2001) 1025-1036
47. Shapiro B.H., Agrawal A.K., and Pampori N.A. Gender differences in drug metabolism regulated by growth hormone. Int. J. Biochem. Cell Biol. 27 (1995) 9-20
48. Song B.J., Matsunaga T., Hardwick J.P., Park S.S., Veech R.L., Yang C.S., Gelboin H.V., and Gonzalez F.J. Stabilization of cytochrome P450j messenger ribonucleic acid in the diabetic rat. Mol. Endocrinol. 1 (1987) 542-547
49. Song B.J., Veech R.L., Park S.S., Gelboin H.V., and Gonzalez F.J. Induction of rat hepatic N-nitrosodimethylamine demethylase by acetone is due to protein stabilization. J. Biol. Chem. 264 (1989) 3568-3572
50. Spracklin D.K., Hankins D.C., Fisher J.M., Thummel K.E., and Kharasch E.D. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J. Pharmacol. Exp. Ther. 281 (1997) 400-411
51. Stolerman I.P. Behavioural pharmacology of nicotine: implications for multiple brain nicotinic receptors. Ciba Found. Symp. 152 (1990) 3-16 discussion 16-22
52. Stolerman I.P., Garcha H.S., and Mirza N.R. Dissociations between the locomotor stimulant and depressant effects of nicotinic agonists in rats. Psychopharmacology (Berl). 117 (1995) 430-437
53. Stoltz C., Vachon M.H., Trottier E., Dubois S., Paquet Y., and Anderson A. The CYP2B2 phenobarbital response unit contains an accessory factor element and a putative glucocorticoid response element essential for conferring maximal phenobarbital responsiveness. J. Biol. Chem. 273 (1998) 8528-8536
54. Stromberg M.F. The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat. Pharmacol. Biochem. Behav. 78 (2004) 743-750
55. Stromberg M.F., Casale M., Volpicelli L., Volpicelli J.R., and O'Brien C.P. A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat. Alcohol 15 (1998) 281-289
56. Styles J.A., Davies A., Lim C.K., De Matteis F., Stanley L.A., White I.N., Yuan Z.X., and Smith L.L. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 15 (1994) 5-9
57. Swan G.E., Carmelli D., and Cardon L.R. Heavy consumption of cigarettes, alcohol and coffee in male twins. J. Stud. Alcohol 58 (1997) 182-190
58. True W.R., Xian H., Scherrer J.F., Madden P.A., Bucholz K.K., Heath A.C., Eisen S.A., Lyons M.J., Goldberg J., and Tsuang M. Common genetic vulnerability for nicotine and alcohol dependence in men. Arch. Gen. Psychiatry 56 (1999) 655-661
59. Tyndale R.F. Genetics of alcohol and tobacco use in humans. Ann. Med. 35 (2003) 94-121
60. Ueno T., and Gonzalez F.J. Transcriptional control of the rat hepatic CYP2E1 gene. Mol. Cell. Biol. 10 (1990) 4495-4505
61. Wang H., and Negishi M. Transcriptional regulation of cytochrome p450 2B genes by nuclear receptors. Curr. Drug. Metab. 4 (2003) 515-525
62. Wang H., and Tompkins L.M. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr. Drug. Metab. 9 (2008) 598-610
63. Ward B.A., Gorski J.C., Jones D.R., Hall S.D., Flockhart D.A., and Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306 (2003) 287-300
64. Wetscher G.J., Bagchi M., Bagchi D., Perdikis G., Hinder P.R., Glaser K., and Hinder R.A. Free radical production in nicotine treated pancreatic tissue. Free Radic. Biol. Med. 18 (1995) 877-882
65. Wilkinson P.K., Sedman A.J., Sakmar E., Kay D.R., and Wagner J.G. Pharmacokinetics of ethanol after oral administration in the fasting state. J. Pharmacokinet. Biopharm. 5 (1977) 207-224
66. Woodcroft K.J., and Novak R.F. Insulin effects on CYP2E1, 2B, 3A, and 4A expression in primary cultured rat hepatocytes. Chem. Biol. Interact. 107 (1997) 75-91
67. Woodcroft K.J., and Novak R.F. Xenobiotic-enhanced expression of cytochromes P450 2E1 and 2B in primary cultured rat hepatocytes. Drug. Metab. Dispos. 26 (1998) 372-378
68. Yue J., Miksys S., Hoffmann E., and Tyndale R.F. Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. J. Psychiatry Neurosci. 33 (2008) 54-63
69. Zhukov A., and Ingelman-Sundberg M. Relationship between cytochrome P450 catalytic cycling and stability: fast degradation of ethanol-inducible cytochrome P450 2E1 (CYP2E1) in hepatoma cells is abolished by inactivation of its electron donor NADPH-cytochrome P450 reductase. Biochem. J. 340 (1999) 453-458